Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: VSIG10 (ImmuneEditome ID:54621)

1. Gene summary of enriched editing regions for VSIG10

Gene summary

Gene information	Gene symbol	VSIG10
	Gene ID	54621
	GeneSynonyms	-
	GeneCytomap	12q24.23
	GeneType	protein-coding
	GeneDescription	V-set and immunoglobulin domain-containing protein 10
	GeneModificationdate	20230528
	UniprotID	Q8N0Z9;F5H724
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr12:118069109-118070449:-	ENST00000359236.8	ENSG00000176834.12	VSIG10	intronic	MIRc,AluSz,AluSp	chr12:118069109-118070449:-.alignment
chr12:118099105-118099444:-	ENST00000536905.4	ENSG00000176834.12	VSIG10	ncRNA_intronic	AluJr,AluJo	chr12:118099105-118099444:-.alignment
chr12:118099105-118099444:-	ENST00000541855.1	ENSG00000176834.12	VSIG10	ncRNA_intronic	AluJr,AluJo	chr12:118099105-118099444:-.alignment
chr12:118099105-118099444:-	ENST00000542011.1	ENSG00000176834.12	VSIG10	ncRNA_intronic	AluJr,AluJo	chr12:118099105-118099444:-.alignment
chr12:118114415-118118471:-	ENST00000321694.5	ENSG00000176834.12	VSIG10	ncRNA_exonic	MER50,AluJb,LTR8,AluSq2,MER41E,L1MB7,MSTD,AluSx1,AluSp	chr12:118114415-118118471:-.alignment
chr12:118114415-118118471:-	ENST00000539956.1	ENSG00000176834.12	VSIG10	ncRNA_exonic	MER50,AluJb,LTR8,AluSq2,MER41E,L1MB7,MSTD,AluSx1,AluSp	chr12:118114415-118118471:-.alignment
chr12:118114415-118118471:-	ENST00000621133.1	ENSG00000176834.12	VSIG10	ncRNA_exonic	MER50,AluJb,LTR8,AluSq2,MER41E,L1MB7,MSTD,AluSx1,AluSp	chr12:118114415-118118471:-.alignment
chr12:118124470-118125188:-	ENST00000539956.1	ENSG00000176834.12	VSIG10	ncRNA_intronic	AluSc8,AluSz	chr12:118124470-118125188:-.alignment
chr12:118124470-118125188:-	ENST00000542011.1	ENSG00000176834.12	VSIG10	ncRNA_intronic	AluSc8,AluSz	chr12:118124470-118125188:-.alignment

Top

2. Tumor-specific enriched editing regions for VSIG10

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr12:118114415-118118471:-	BRCA	EER	2.8756e-03
ENSG00000176834.12,VSIG10	BRCA	EAG	5.0032e-03
ENSG00000176834.12,VSIG10	LIHC	EAG	4.8454e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr12:118114415-118118471:-	STAD	Path	EER	1.7834e-02	1.9346e-03	0.2448

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr12:118114415-118118471:-	UCS	EER	3.1802e-02	3.3745e-02	1.6970e-06
ENSG00000176834.12,VSIG10	UCS	EAG	3.1802e-02	3.3745e-02	1.6970e-06

Top

3. Enriched editing regions and immune related genes for VSIG10

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr12:118114415-118118471:-

UVM

EER

ENSG00000135622,SEMA4F

0.3938

2.5200e-02

6.0710e-04

0.4140

DGCR8;ELAVL1;FUS

SEMA4F

T_cells_CD4_memory_activated

GSVA_HALLMARK_HEME_METABOLISM

chr12:118114415-118118471:-

UVM

EER

ENSG00000170390,DCLK2

0.3879

3.0841e-02

5.4396e-04

0.4173

DGCR8;ELAVL1;FUS

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MYC_TARGETS_V2

chr12:118114415-118118471:-

UVM

EER

ENSG00000156298,TSPAN7

0.3728

3.8069e-02

4.3686e-04

0.4237

DGCR8;ELAVL1;FUS

NK_cells_resting

GSVA_HALLMARK_MYC_TARGETS_V2

chr12:118114415-118118471:-

UVM

EER

ENSG00000178498,DTX3

0.3583

4.6176e-02

5.2107e-04

0.4185

DGCR8;ELAVL1;FUS

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MYC_TARGETS_V1

chr12:118114415-118118471:-

UVM

EER

ENSG00000135622,SEMA4F

0.3938

2.5200e-02

6.0710e-04

0.4140

DGCR8;ELAVL1;FUS

SEMA4F

T_cells_CD4_memory_activated

GSVA_HALLMARK_HEME_METABOLISM

chr12:118114415-118118471:-

UVM

EER

ENSG00000170390,DCLK2

0.3879

3.0841e-02

5.4396e-04

0.4173

DGCR8;ELAVL1;FUS

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MYC_TARGETS_V2

chr12:118114415-118118471:-

UVM

EER

ENSG00000156298,TSPAN7

0.3728

3.8069e-02

4.3686e-04

0.4237

DGCR8;ELAVL1;FUS

NK_cells_resting

GSVA_HALLMARK_MYC_TARGETS_V2

chr12:118114415-118118471:-

UVM

EER

ENSG00000178498,DTX3

0.3583

4.6176e-02

5.2107e-04

0.4185

DGCR8;ELAVL1;FUS

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MYC_TARGETS_V1

chr12:118114415-118118471:-

UVM

EER

ENSG00000135622,SEMA4F

0.3938

2.5200e-02

6.0710e-04

0.4140

DGCR8;ELAVL1;FUS

SEMA4F

T_cells_CD4_memory_activated

GSVA_HALLMARK_HEME_METABOLISM

chr12:118114415-118118471:-

UVM

EER

ENSG00000170390,DCLK2

0.3879

3.0841e-02

5.4396e-04

0.4173

DGCR8;ELAVL1;FUS

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MYC_TARGETS_V2

chr12:118114415-118118471:-

UVM

EER

ENSG00000156298,TSPAN7

0.3728

3.8069e-02

4.3686e-04

0.4237

DGCR8;ELAVL1;FUS

NK_cells_resting

GSVA_HALLMARK_MYC_TARGETS_V2

chr12:118114415-118118471:-

UVM

EER

ENSG00000178498,DTX3

0.3583

4.6176e-02

5.2107e-04

0.4185

DGCR8;ELAVL1;FUS

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MYC_TARGETS_V1

More results

Top

4. Enriched editing regions and immune related splicing for VSIG10

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

5. Enriched editing regions and immune infiltration for VSIG10

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr12:118114415-118118471:-	ACC	EER	NK_cells_resting	4.9795e-02	-0.3391
ENSG00000176834.12,VSIG10	ACC	EAG	NK_cells_resting	3.3650e-02	-0.3600
chr12:118114415-118118471:-	BRCA	EER	T_cells_CD4_memory_resting	2.3768e-02	0.0865
ENSG00000176834.12,VSIG10	BRCA	EAG	T_cells_CD4_memory_resting	1.8099e-02	0.0898
chr12:118114415-118118471:-	CESC	EER	T_cells_gamma_delta	7.9277e-03	-0.3316
ENSG00000176834.12,VSIG10	CESC	EAG	T_cells_regulatory_(Tregs)	3.3443e-02	0.2564
ENSG00000176834.12,VSIG10	COAD	EAG	Eosinophils	1.5839e-04	0.4919
chr12:118114415-118118471:-	ESCA	EER	Macrophages_M2	2.4920e-04	0.4634
ENSG00000176834.12,VSIG10	ESCA	EAG	Macrophages_M2	1.3792e-02	0.2632
chr12:118114415-118118471:-	GBM	EER	T_cells_regulatory_(Tregs)	4.6946e-02	0.1873
ENSG00000176834.12,VSIG10	HNSC	EAG	Neutrophils	5.9758e-03	-0.4378
chr12:118114415-118118471:-	KICH	EER	T_cells_gamma_delta	1.0485e-02	0.3425
ENSG00000176834.12,VSIG10	KICH	EAG	T_cells_gamma_delta	1.0485e-02	0.3425
chr12:118114415-118118471:-	KIRC	EER	T_cells_follicular_helper	1.4979e-02	-0.1997
ENSG00000176834.12,VSIG10	KIRC	EAG	T_cells_follicular_helper	8.7267e-03	-0.2093
chr12:118114415-118118471:-	KIRP	EER	T_cells_gamma_delta	1.9346e-03	-0.2196
ENSG00000176834.12,VSIG10	KIRP	EAG	T_cells_gamma_delta	3.7968e-03	-0.2038
chr12:118114415-118118471:-	LGG	EER	T_cells_follicular_helper	2.5762e-02	-0.1215
ENSG00000176834.12,VSIG10	LGG	EAG	T_cells_follicular_helper	2.5738e-02	-0.1215
chr12:118114415-118118471:-	LUAD	EER	Eosinophils	1.1250e-02	0.2366
ENSG00000176834.12,VSIG10	LUAD	EAG	Eosinophils	1.0782e-02	0.2282
chr12:118114415-118118471:-	PCPG	EER	Neutrophils	3.8207e-04	0.6776
ENSG00000176834.12,VSIG10	PCPG	EAG	Neutrophils	3.8207e-04	0.6776
chr12:118114415-118118471:-	PRAD	EER	T_cells_CD4_memory_resting	5.9395e-04	0.1697
ENSG00000176834.12,VSIG10	PRAD	EAG	T_cells_CD4_memory_resting	7.5755e-04	0.1665
chr12:118114415-118118471:-	SKCM	EER	NK_cells_activated	4.5184e-02	-0.1856
ENSG00000176834.12,VSIG10	SKCM	EAG	NK_cells_activated	4.4891e-02	-0.1858
chr12:118069109-118070449:-	STAD	EER	T_cells_CD8	4.6907e-02	0.2124
chr12:118114415-118118471:-	STAD	EER	Mast_cells_resting	8.4559e-03	0.2038
ENSG00000176834.12,VSIG10	STAD	EAG	Macrophages_M0	7.4813e-03	-0.1819
chr12:118069109-118070449:-	TGCT	EER	Macrophages_M0	2.4382e-03	0.3617
chr12:118114415-118118471:-	TGCT	EER	T_cells_CD4_memory_resting	3.9737e-03	0.4879
ENSG00000176834.12,VSIG10	TGCT	EAG	Macrophages_M1	2.2522e-03	-0.3252
chr12:118114415-118118471:-	UCEC	EER	T_cells_regulatory_(Tregs)	2.3387e-02	0.2708
ENSG00000176834.12,VSIG10	UCEC	EAG	T_cells_regulatory_(Tregs)	2.8508e-02	0.2601
chr12:118114415-118118471:-	UVM	EER	NK_cells_activated	3.0107e-02	-0.2692
ENSG00000176834.12,VSIG10	UVM	EAG	NK_cells_activated	3.0107e-02	-0.2692

Top

6. Enriched editing regions and immune gene sets for VSIG10

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr12:118114415-118118471:-	ACC	GSVA_HALLMARK_GLYCOLYSIS	EER	4.3506e-02	-0.3483
ENSG00000176834.12,VSIG10	ACC	GSVA_HALLMARK_GLYCOLYSIS	EAG	4.8687e-02	-0.3357
ENSG00000176834.12,VSIG10	BLCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	1.0080e-03	0.2685
chr12:118114415-118118471:-	BLCA	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.0261e-03	0.2869
chr12:118114415-118118471:-	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	7.4632e-08	-0.2040
ENSG00000176834.12,VSIG10	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	2.6210e-07	-0.1941
ENSG00000176834.12,VSIG10	COAD	GSVA_HALLMARK_DNA_REPAIR	EAG	4.4167e-06	-0.5794
chr12:118069109-118070449:-	ESCA	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	4.9340e-02	0.3090
chr12:118114415-118118471:-	ESCA	GSVA_HALLMARK_PROTEIN_SECRETION	EER	2.9267e-02	-0.2864
ENSG00000176834.12,VSIG10	GBM	GSVA_HALLMARK_PEROXISOME	EAG	7.7177e-04	-0.3106
chr12:118114415-118118471:-	GBM	GSVA_HALLMARK_PEROXISOME	EER	9.7894e-04	-0.3060
ENSG00000176834.12,VSIG10	HNSC	GSVA_HALLMARK_INFLAMMATORY_RESPONSE	EAG	2.0924e-03	-0.4837
chr12:118114415-118118471:-	KIRC	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	2.2525e-03	0.2492
ENSG00000176834.12,VSIG10	KIRC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	4.7106e-04	0.2767
ENSG00000176834.12,VSIG10	KIRP	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	8.9904e-03	0.1843
chr12:118114415-118118471:-	KIRP	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	7.4356e-03	0.1902
chr12:118114415-118118471:-	LIHC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.6739e-05	-0.2469
ENSG00000176834.12,VSIG10	LIHC	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	3.5991e-05	-0.2426
chr12:118114415-118118471:-	LUAD	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.7492e-02	0.2222
chr12:118114415-118118471:-	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	4.1510e-02	0.1744
ENSG00000176834.12,VSIG10	OV	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	5.6386e-03	-0.1687
chr12:118069109-118070449:-	OV	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	2.9780e-02	-0.4039
chr12:118114415-118118471:-	OV	GSVA_HALLMARK_G2M_CHECKPOINT	EER	6.8692e-03	-0.1648
ENSG00000176834.12,VSIG10	PCPG	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.7264e-02	-0.4913
chr12:118114415-118118471:-	PCPG	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.7264e-02	-0.4913
chr12:118114415-118118471:-	PRAD	GSVA_HALLMARK_MYC_TARGETS_V2	EER	1.0681e-04	-0.1911
ENSG00000176834.12,VSIG10	PRAD	GSVA_HALLMARK_MYC_TARGETS_V2	EAG	9.8248e-05	-0.1921
ENSG00000176834.12,VSIG10	SARC	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.6048e-02	0.3233
chr12:118114415-118118471:-	SARC	GSVA_HALLMARK_HEME_METABOLISM	EER	1.6129e-02	0.3260
ENSG00000176834.12,VSIG10	SKCM	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	3.9937e-02	-0.1902
chr12:118114415-118118471:-	SKCM	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	3.8078e-02	-0.1920
chr12:118069109-118070449:-	STAD	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	2.6878e-02	0.2360
chr12:118099105-118099444:-	STAD	GSVA_HALLMARK_NOTCH_SIGNALING	EER	4.5528e-03	-0.5201
ENSG00000176834.12,VSIG10	STAD	GSVA_HALLMARK_MYOGENESIS	EAG	1.8809e-03	0.2108
chr12:118114415-118118471:-	STAD	GSVA_HALLMARK_GLYCOLYSIS	EER	1.8179e-06	-0.3606
ENSG00000176834.12,VSIG10	TGCT	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	5.5723e-09	0.5781
chr12:118069109-118070449:-	TGCT	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.6688e-04	0.4285
chr12:118114415-118118471:-	TGCT	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	1.4084e-03	0.5329
chr12:118114415-118118471:-	THCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	1.9194e-02	0.2060
ENSG00000176834.12,VSIG10	THCA	GSVA_HALLMARK_P53_PATHWAY	EAG	8.6846e-03	-0.2108
ENSG00000176834.12,VSIG10	THYM	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	8.7710e-03	0.3471
chr12:118114415-118118471:-	THYM	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.9010e-03	0.4061
chr12:118114415-118118471:-	UCEC	GSVA_HALLMARK_SPERMATOGENESIS	EER	2.0702e-03	-0.3621
ENSG00000176834.12,VSIG10	UCEC	GSVA_HALLMARK_SPERMATOGENESIS	EAG	3.9525e-03	-0.3379

Top

7. Enriched editing regions and drugs for VSIG10

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr12:118114415-118118471:-	ACC	BMS.754807	EER	1.0983e-02	0.4308
ENSG00000176834.12,VSIG10	ACC	BMS.754807	EAG	8.9251e-03	0.4355
ENSG00000176834.12,VSIG10	BLCA	ATRA	EAG	2.3162e-02	-0.1872
chr12:118114415-118118471:-	BLCA	BIBW2992	EER	2.2339e-02	0.2018
chr12:118114415-118118471:-	BRCA	AP.24534	EER	1.4480e-03	-0.1216
ENSG00000176834.12,VSIG10	BRCA	AP.24534	EAG	3.0185e-03	-0.1125
chr12:118114415-118118471:-	CESC	KIN001.135	EER	4.7752e-02	-0.2504
ENSG00000176834.12,VSIG10	COAD	AZD6482	EAG	1.0136e-07	-0.6505
ENSG00000176834.12,VSIG10	ESCA	Elesclomol	EAG	6.5567e-05	-0.4145
chr12:118069109-118070449:-	ESCA	KU.55933	EER	2.4829e-03	-0.4599
chr12:118114415-118118471:-	ESCA	AS601245	EER	4.2165e-03	-0.3703
ENSG00000176834.12,VSIG10	GBM	LFM.A13	EAG	4.0272e-03	-0.2674
chr12:118114415-118118471:-	GBM	LFM.A13	EER	3.0430e-03	-0.2764
ENSG00000176834.12,VSIG10	HNSC	Embelin	EAG	4.5728e-03	0.4501
chr12:118114415-118118471:-	KIRC	Dasatinib	EER	1.4753e-02	0.2008
ENSG00000176834.12,VSIG10	KIRC	Dasatinib	EAG	8.9199e-03	0.2094
ENSG00000176834.12,VSIG10	KIRP	Metformin	EAG	5.0818e-03	0.1974
chr12:118114415-118118471:-	KIRP	Metformin	EER	1.4427e-02	0.1741
chr12:118114415-118118471:-	LGG	Embelin	EER	1.0186e-02	-0.1398
ENSG00000176834.12,VSIG10	LGG	Embelin	EAG	9.7654e-03	-0.1406
chr12:118114415-118118471:-	LIHC	GSK.650394	EER	4.2224e-04	-0.2082
ENSG00000176834.12,VSIG10	LIHC	GSK.650394	EAG	3.0353e-04	-0.2128
ENSG00000176834.12,VSIG10	LUSC	BMS.754807	EAG	4.2311e-02	0.1725
chr12:118114415-118118471:-	LUSC	BMS.754807	EER	4.8504e-02	0.1689
chr12:118069109-118070449:-	OV	BMS.509744	EER	3.1625e-02	-0.3999
ENSG00000176834.12,VSIG10	OV	Bryostatin.1	EAG	2.1909e-02	-0.1400
chr12:118114415-118118471:-	OV	Bryostatin.1	EER	1.5871e-02	-0.1472
ENSG00000176834.12,VSIG10	PRAD	Embelin	EAG	1.4919e-04	-0.1871
chr12:118114415-118118471:-	PRAD	Embelin	EER	2.2327e-04	-0.1822
chr12:118114415-118118471:-	SARC	AUY922	EER	3.8665e-03	0.3868
ENSG00000176834.12,VSIG10	SARC	AUY922	EAG	3.7529e-03	0.3845
ENSG00000176834.12,VSIG10	SKCM	Bicalutamide	EAG	3.9675e-03	-0.2644
chr12:118114415-118118471:-	SKCM	Bicalutamide	EER	4.9006e-03	-0.2584
chr12:118099105-118099444:-	STAD	GSK.650394	EER	4.5962e-02	0.3802
chr12:118114415-118118471:-	STAD	AP.24534	EER	2.1049e-07	-0.3897
ENSG00000176834.12,VSIG10	STAD	AZD.0530	EAG	5.3784e-08	-0.3637
chr12:118069109-118070449:-	STAD	Gemcitabine	EER	9.0247e-04	-0.3477
chr12:118114415-118118471:-	TGCT	AZD.0530	EER	2.0801e-04	-0.6024
ENSG00000176834.12,VSIG10	TGCT	AZD.0530	EAG	2.3810e-07	-0.5231
chr12:118069109-118070449:-	TGCT	Dasatinib	EER	9.1334e-03	-0.3139
chr12:118114415-118118471:-	THCA	ABT.263	EER	1.2596e-02	-0.2191
ENSG00000176834.12,VSIG10	THCA	AZD8055	EAG	1.2421e-03	-0.2579
chr12:118114415-118118471:-	THYM	Imatinib	EER	3.4561e-04	-0.4613
ENSG00000176834.12,VSIG10	THYM	Imatinib	EAG	1.9864e-03	-0.4045
ENSG00000176834.12,VSIG10	UCEC	AZD6244	EAG	9.1241e-04	-0.3851
chr12:118114415-118118471:-	UCEC	Bexarotene	EER	4.1463e-03	-0.3386
ENSG00000176834.12,VSIG10	UVM	CCT007093	EAG	7.2108e-03	-0.3303
chr12:118114415-118118471:-	UVM	CCT007093	EER	7.2108e-03	-0.3303

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType